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Summary
Development of strategies for induction of HIV-1 broadly neutralizing antibodies (bnAbs) by
vaccines is a priority. Determining the steps of bnAb induction in HIV-1-infected individuals who
make bnAbs is a key strategy for immunogen design. Here we study the B cell response in a
bnAb-producing individual, and report cooperation between two B cell lineages to drive bnAb
development. We isolated an autologous virus-neutralizing antibody lineage that targeted an
envelope region (loop D) and selected virus escape mutants that resulted in both enhanced bnAb
lineage envelope binding and escape mutant neutralization—traits associated with increased B cell
antigen drive. Thus, in this individual, two B cell lineages cooperated to induce the development
of bnAbs. Design of vaccine immunogens that simultaneously drive both autologous and broadly
neutralizing B cell lineages may be important for vaccine-induced recapitulation of events that
transpire during the maturation of neutralizing antibodies in HIV-1-infected individuals.
Introduction
The development of a successful HIV-1 vaccine has been stymied by the inability to induce
broadly neutralizing antibodies (bnAbs) to conserved regions of the HIV-1 envelope
glycoprotein (Env) (Burton et al., 2012; Mascola and Haynes, 2013), that include the CD4
binding site (CD4bs), the membrane external proximal region, and glycans and amino acid
residues in the regions of the first (V1), second (V2) and third (V3) loops (Burton et al.,
2012; Kwong and Mascola, 2012; Sattentau and McMichael, 2010; Stamatatos, 2012;
Walker et al., 2011; Walker et al., 2009; Zhou et al., 2010). To date, all bnAbs isolated have
one or more unusual characteristics: high levels of somatic hypermutations, long heavy
chain third complementarity determining regions (HCDR3), or poly- or auto-reactivity to
non-HIV-1 antigens (Haynes et al., 2005; Haynes et al., 2012; Kwong and Mascola, 2012;
Mouquet and Nussenzweig, 2012; Scheid et al., 2009) —all antibody traits influenced by
various host tolerance mechanisms (Haynes et al., 2012; Mascola and Haynes, 2013;
Mouquet and Nussenzweig, 2012). As a consequence of these antibody traits, bnAbs appear
to be disfavored and difficult to induce with traditional immunization regimens (Haynes et
al., 2012; Mascola and Haynes, 2013; Mascola and Montefiori, 2010; Montefiori et al.,
2012). We and others have suggested strategies whereby immunogens are selected to react
with bnAb lineage members at multiple stages in their development in an effort to drive
otherwise unfavored antibody pathways (Haynes et al., 2012; Liao et al., 2013a; Mascola
and Haynes, 2013).
One approach to dissect the mechanisms underlying bnAb development is to identify the
drivers that are responsible for the sequential stimulation of HIV-1 reactive B cell lineages
in chronically infected individuals over time (Bonsignori et al., 2011; Corti et al., 2010;
Gray et al., 2011; Hraber et al., 2014; Klein et al., 2012; Lynch et al., 2012; Moore et al.,
2009; Moore et al., 2011; Tomaras et al., 2011; Walker et al., 2011). We have recently
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identified an African individual (CH505) in whom HIV-1 infection was established by a
single subtype C transmitted/founder (T/F) virus, and mapped the co-evolution of CD4bs
bnAbs (the CH103 bnAb B cell lineage) and CH505 T/F virus over time (Liao et al., 2013a).
The T/F Env continuously diversified over time under the selection pressure of bnAbs and,
concurrently, the inferred unmutated common ancestor (UCA) of the CH103 B cell lineage
accumulated somatic mutations leading to gradual acquisition of bnAb activity (Liao et al.,
2013a). While the minimally mutated early members of this lineage neutralized only the T/F
virus, the later, more mature members of the CH103 clonal lineage potently neutralized both
the CH505 T/F and 55% of multi-clade heterologous HIV-1 strains (Liao et al., 2013a).
These data engendered interest in determining the autologous virus Env variants that
stimulated the development of this broadly neutralizing CH103 antibody lineage. Co-crystal
structure of the CH103 antibody and the HIV-1 Env revealed antibody contacts in the V5,
CD4-binding loop, and loop D regions in Env, and analysis of the env gene sequences
obtained by single genome amplification demonstrated additional early mutations in the V1
and V4 loop regions (Liao et al., 2013a).
In this study, we have probed the mechanisms of selection of early CH505 Env mutations,
and found that amino acid changes in the V1, V4, V5 and CD4-binding loop resulted in
escape from neutralization by the CH103 lineage (V1, V5, CD4-binding loop) or from
cytotoxic T cell pressure (V4). Surprisingly, however, the mutations in the Env loop D
increased neutralization sensitivity to the CH103 bnAb lineage. We demonstrated a
mechanism of bnAb induction wherein a second non-bnAb antibody lineage targeted a bnAb
contact site, thus selecting Env variants with enhanced binding and neutralization sensitivity
for bnAb B cell lineage antibodies. These results demonstrated that cooperation between two
B cell lineages early in HIV-1 infection facilitated the induction of broadly neutralizing
CD4bs antibodies.
Results
Early CH505 Env mutations in V1, V4, V5 and the CD4bs were associated with escape from
CH103 bnAbs or T cell responses
To study the interplay between HIV-1 Env variants and bnAb development in the CH505
individual, we determined neutralization susceptibility of 124 Env pseudoviruses (~18 per
time point) from six time points after HIV-1 transmission (weeks 4, 20, 30, 53, 78 and 100)
to members of the CH103 bnAb lineage (Fig. 1 and Fig. S1). The CH103 UCA and
intermediate antibody (IA) 8 through IA4 only neutralized the CH505 T/F virus. Over time
(weeks 14–100), CH505 viruses gradually became more resistant to subsets of the CH103
bnAb lineage antibodies. By week 53, all virus variants were resistant to the early members
of the CH103 antibody lineage (UCA and IA8-4). For lineage members that exhibited
increased heterologous neutralization (IA3-IA1 and mature CH103, CH104, CH105 and
CH106 CD4bs bnAbs), escape was less complete, with a spectrum of sensitive and resistant
autologous virus variants isolated from each time point (Fig. 1 and Table S1). Thus,
pseudoviruses were categorized into sensitive and resistant groups and analyzed for location
of accumulated mutations in the env gene (Fig. 1).
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Env sequence analysis showed that all but one of the 20 viruses resistant to early IAs (IA8-
IA4) at week 30 contained insertions (3–12 amino acids) in V1 (Fig. 2a). Importantly, the
V1 insertions also added 1–4 potential N-linked glycosylation (PNLG) sites (Fig. 2a and
Fig. S2). Although V1 was not seen in the Env-CH103 co-crystal structure (Liao et al.,
2013a), a recent cryo-EM structure of the fully glycosylated Env trimer showed that V1/V2
could significantly affect the binding and neutralization of CD4bs bnAbs (Lyumkis et al.,
2013). Docking the CH103 bnAb and CH505 Env sequences on the cryo-EM structure
showed that an enlarged V1 loop with potential extra glycan(s) might push V2 into positions
incompatible with early IA binding (Fig. S2a and S2b). All but one of the 16 viruses
resistant to later IAs (IA3-IA1) and mature CH103 mAbs had a 2 or 7-amino acid insertions
in V5, which is a major Env contact site for the CH103 bnAb heavy chain (Liao et al.,
2013a). All resistant viruses from weeks 53, 78 and 100 had insertions in V5 (Fig. 1 and Fig.
S1). The 2- amino acid (Asp and Thr) insertions could push loop V5 and the glycan at
position 461 into a possible clashing position with the light chain of CH103 antibodies (Fig.
S2c). Introduction of the Asp and Thr into V5 in the T/F Env confirmed that this 2-amino
acid insertion indeed conferred resistance to CH103 lineage mAbs (Fig. S2d). We also found
one mutation (S365P) in the CD4 binding loop that resulted in a pseudovirus (w14.12) that
completely escaped from all members of the CH103 lineage except for weak neutralization
susceptibility to mAb CH103 (Fig. 1 and Fig. S1). These results indicated that early
insertions in the V1 and V5 loops as well as site mutations in the CD4 binding loop resulted
from CH103 bnAb mediated selection pressure.
Mutations in V4 were found early on at week 7 and persisted throughout later time points,
suggesting that they were strongly selected (Fig. S1). Viruses with mutations in a 9-amino
acid region in V4 were predominant (78%) as early as week 7 and completely replaced the
T/F virus population from week 14 onward (Fig. S1 and S3a). The N279K mutation in loop
D was detected at as early as week 4 (10%), peaked at week 7 (57%), and disappeared from
week w14 onward (Fig. 3a and Fig. S1). In addition, the V281A and V281G mutations were
detected at week 7 and week 9, respectively, and both become predominant in later time
points together with other mutations in a 9-amino acid region in loop D (Fig. 3a). Since the
mutations in both regions occurred early and their patterns were typical for T cell escape
mutations, we performed ELISpot analysis using autologous overlapping peptides to
determine if those mutations were driven by CD8+ T cell responses.
A CD8+ T cell response was detected for a putative T cell epitope (NSTRTITIHC) in V4
(Fig. S3b and Table S2). The same peptides containing a T415K mutation, which were
detected at week 14, could not be recognized by CD8+ T cells. Four mutants containing
individual V4 mutations, including the T415K, had similar neutralization susceptibility to
CH103 lineage mAbs as the T/F virus (Fig. S3c). These results demonstrated that the
predominant mutations in V4 were driven by CD8+ T cell responses. In contrast, no T cell
responses were found targeting the loop D or V1, V3 and V5 regions (Table S2).
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Selection of the loop D mutations in CH505 envelope by potent autologous non-CH103
Abs
Since the Env loop D region is a binding site for CH103 lineage bnAbs (15), we next asked
if loop D mutations might be due to the selection by CH103 lineage CD4bs antibodies. To
test this hypothesis, we introduced loop D mutations at positions 275, 279, 280 and 281,
individually or in combination as they occurred in vivo, into the T/F env gene to determine
their effect on Env pseudovirus sensitivity to neutralization by the autologous CH103
lineage mAbs. Unexpectedly, all loop D mutations rendered the mutant Env pseudoviruses
4.5-fold (range, 0.4–20) more sensitive than the T/F virus to neutralization by CH103
lineage bnAbs (Fig. 3b and Table S3). In addition, when compared to the CH505 T/F virus,
four loop D mutants (M5N279K, M6V281A, M7E275K/N279D/V281S and M10V281G) with one or
three mutations were less fit than the T/F virus (Fig. S3d). These results demonstrated that
the loop D mutations were selected by an antibody lineage other than the CH103 bnAb
lineage.
To isolate the antibodies responsible for the loop D mutations, we established limiting
dilution cell cultures from peripheral blood memory B cells collected at week 41 in CH505
(Bonsignori et al., 2011). We chose week 41 to study because neutralization of heterologous
tier 2 viruses was first detected at week 41, 21 weeks after the detection of the first
autologous neutralization activity. We identified one mAb, CH235 (VH1–46, Vk3–15), that
neutralized the CH505 T/F but belonged to a clonal family distinct from CH103 lineage
(VH4–59, Vλ3-1). MAb CH235 neutralized the CH505 T/F virus ~7 fold more potently than
antibody CH103 (Fig. 3c). However, CH235 poorly neutralized loop D mutant
M11N279D/V281G and could not neutralize five other loop D mutants (M7E275K/N279D/V281S ,
M8N280S/V281A, M9E275K/N279D/V281G , M20N280S/V281G and M21N280T/V281A). In contrast,
CH103 neutralized the same five loop D mutants ~10-fold better than the CH505 T/F virus
(Fig. 3c).
To identify antibody members of the CH235 lineage, we analyzed limiting dilution memory
B cell cultures from week 41 and identified four additional CH235 lineage members
(CH236, CH239, CH240, and CH241). The frequency of CH235 clonal lineage memory B
cells at week 41 post-transmission was 0.018%, which was similar to that (0.014%) of the
CH103 bnAb lineage. The four CH103 lineage antibodies isolated at week 41 were of
similar mutation frequencies as inferred antibodies of the neutralization arm of the CH103
lineage (Fig. S4). To confirm the relevance of the inferred IAs of the CH103 lineage, we
characterized these newly isolated four natural IAs (CH186, CH187, CH188 and CH200) of
the CH103 bnAb lineage from week 41 and demonstrated that their neutralization specificity
was similar to that of the inferred IAs with only neutralization of the autologous CH505 T/F
virus but no neutralization of heterologous viruses (Fig. S4).
We inferred the CH235 lineage UCA and IAs, and expressed all CH235 lineage members as
IgG1 recombinant antibodies (Liao et al., 2013a) (Fig. S5). We then determined the ability
of the CH235 lineage antibodies to neutralize the CH505 T/F and its variants. Like CH103
lineage mAbs, the CH235 UCA did not neutralize the CH505 T/F virus, with neutralization
capacity acquired at IA3 (Fig. 4 and Table S4). The CH235 lineage mAbs could partially
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neutralize week 30 viruses, but could not neutralize the majority of viruses from weeks 53–
100 after these viruses acquired loop D mutations. These results demonstrated that CH235
lineage mAbs had a neutralization profile distinct from the CH103 bnAb lineage, in that they
potently neutralized early autologous viruses and then at week 53 selected viruses that
completely escaped CH235 lineage neutralization.
To determine whether the escape from CH235 lineage mAbs was indeed due to loop D
mutations, we determined the ability of CH235 lineage mAbs to neutralize the CH505 loop
D mutants. CH235 lineage antibodies neutralized the early loop D mutants (M5N279K,
M6V281A, M10V281G) that occurred before week 30 equally well or better than the T/F virus
(Fig. 5 and Table S5). These mutants have only one mutation at position 279 or 281.
However, the CH235 lineage mAbs only partially neutralized loop D mutants M19V281D
and M11N279D/V281G that were first detected at week 30, and could not neutralize the five
loop D mutants representing CH505 variants at week 30 or later time points
(M8N280S/V281A , M9E275K/279D/V281G , M7E275K/N279D/V281S , M20N280S/V281G and
M21N280T/V281A). Thus, we have identified a second clonal lineage (CH235) of neutralizing
antibodies from the CH505 individual that selected early loop D Env mutations.
Mutations in Loop D enhance interactions between Env gp120 and CH103 bnAbs
Based on our previous co-crystal structure of Env and CH103 (Liao et al., 2013a), the T/F
Env favored the interaction with the CH103 UCA (Fig. 6a). However, the loop D mutant
M7E275K/N279D/V281S that contained three mutations favorably bound the mature CH103,
which contained three CDR L2 mutations (Q50E, D51N and S52Y) compared to the UCA
(Fig. 6b). When all critical mutations in loop D and CDR L2 were reverted back to those in
the T/F Env and CH103 UCA, respectively, all but one of eight revertants had unfavorable
binding energy change (ΔΔG) (Fig. 6c). This suggested that the coevolution of the CH505
loop D and CH103 lineage antibodies led to better binding between loop D mutants and
mature CH103 antibodies, while the reversion mutation in either Env or CH103 bnAb
resulted in reduced binding. In the CH505 Env evolution, analysis of longitudinal sequences
demonstrated that single loop D Env mutations were selected early, followed by multiple
loop D mutations at later time points; most of these mutations occurred at positions 279 and
281 (Fig. 3a). The sequential accumulation of mutations from simple to complex forms in
loop D might have gradually selected the mutations at the binding site in CDR L2 with
continuously increased binding affinity. Thus, the improved binding between the loop D
mutants and CDR L2 of mature CH103 might have driven the further maturation of CH103
lineage mAbs.
CH103 lineage bnAbs bound to the loop D mutant Envs more efficiently than the T/F Env
We next asked whether the CH505 Envs with the loop D mutants could bind to the CH103
lineage members better than the CH505 T/F Env, a trait thought to be necessary to drive
antibody lineage maturation (Dal Porto et al., 2002; Dal Porto et al., 1998; Schwickert et al.,
2011; Shih et al., 2002). Seven loop D mutant Envs were expressed as gp140s, M6V281A and
M10V281G with individual mutations, M8N280S/V281A, M11N279D/V281G and
M21 N280T/V281A with two mutations, and M7 E275K/N279D/V281S and M9 E275K/N279D/V281G
with three mutations (Fig. 3b). We then determined their binding by ELIS A to all members
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in the CH103 and CH235 lineages (Fig. S6). The M6V281A, M10V281G and M11N279D/V281G
Loop D mutant Envs bound to nearly all CH103 clonal lineage members better than the T/F
Env (Fig. 3d), while M8N280S/V281A, M9E275K/N279D/V281G and M21N280T/V281A mutant
Envs bound less well than the T/F Env to early CH103 lineage members (UCA through IA4)
(Fig. 3d). All seven loop D mutant Envs also bound to four natural IAs (CH186, CH187,
CH188 and CH200) of the CH103 bnAb lineage better than the T/F Env (Fig. S4D). Thus, it
is likely that CH505 Env loop D mutant viruses drove the maturation of the CH103 lineage
by targeting early lineage members through mutations at amino acid positions 281 and 279,
and late CH103 lineage members by a combinations of mutations at amino acid positions
280, 281, 279 and/or 275 (Fig. 3a and 3d).
In contrast, when compared to the T/F Env, mature CH235 mAbs and IA3-IA1 bound loop
D mutant Envs at least 100 fold lower than the T/F Env, except that they bound to M6V281A
Env better than the T/F Env (Fig. 3d). While none of the loop D mutants or the CH505 T/F
Env bound the CH235 UCA or IA4 by ELISA, the T/F Env did weakly react with the
CH235 UCA at ~10µM as determined by surface plasmon resonance (Table S6). These
results strongly support the hypothesis that the CH235 lineage mAbs selected the loop D
mutant Envs that had lower binding to the CH235 lineage mAbs, but higher binding to, and
enhanced neutralization by, the CH103 lineage mAbs (Fig. 7).
Discussion
One fundamental question in HIV-1 vaccine design is how immunogens can be optimized to
drive the maturation of bnAbs in vivo. By studying the HIV-1 quasispecies evolution in an
individual (CH505) with a single TF virus, and by mapping the neutralization susceptibility
of early quasispecies members to the autologous CH103 lineage, we have shown that the
maturation of the CD4bs bnAb lineage was driven by cooperation of two neutralizing
antibody B cell lineages. This observation came from the surprising finding that one of the
contact sites of the CH103 bnAb light chain (the Env loop D) contained mutations that did
not lead to escape from the CH103 bnAb lineage, but in contrast, resulted in enhanced
binding and neutralization of loop D mutant viruses by the CH103 bnAb lineage. These data
demonstrated that the CH103 bnAb lineage members did not select the loop D mutants in
CH505 Env, but rather suggested the existence of autologous neutralizing antibodies that
could neutralize the CH505 T/F virus, but not neutralize loop D mutant viruses. Thus, these
observations led to the isolation of the CH235 lineage, and the demonstration that this
autologous neutralizing lineage indeed selected loop D escape mutants.
The concept of V1V2 glycan bnAbs evolving from autologous neutralizing antibody
lineages has been recently put forth (Doria-Rose et al., 2014; Liao et al., 2013a; Moore et
al., 2012; Wibmer et al., 2013). Moore and colleagues demonstrated that autologous
polyclonal plasma neutralizing antibodies targeted at subsequent sites of V1V2 bnAbs could
be documented (Moore et al., 2012; Wibmer et al., 2013). Our studies differ from these
studies in that we have used recombinant antibody techniques to isolate entire clonal
lineages to directly demonstrate their cooperation in induction of CD4bs bnAbs. While it is
clear that bnAbs develop heterologous broad neutralizing capacity by neutralizing
autologous virus Env mutant viruses (Doria-Rose et al., 2014; Liao et al., 2013a), our study
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directly demonstrates the mechanism of how this can happen at the B cell lineage level.
These observations of two lineages cooperating to drive a bnAb lineage provide a view of
how one lineage can be affected by another to accommodate autologous Env variation.
Thus, the cooperation between the CH235 and CH103 lineages represents a novel molecular
mechanism of bnAb development, wherein one non-bnAb lineage (CH235) selected escape
mutations in an Env contact site (loop D) that led to increased binding and neutralization of
the other bnAb lineage (CH103), ultimately driving the maturation and development of
broadly cross-reactive neutralizing antibodies (Fig. 7). It has been unclear how bnAbs can
acquire heterologous breadth of neutralization respond to evolving T/F variants. Our studies
show that one mechanism for achieving this is via cooperating lineages that select virus
mutants with more bnAb lineage neutralization sensitivity than the T/F virus, thus
potentiating bnAb affinity maturation.
The contrast in selection of autologous escape mutants by the CH103 bnAb lineage (Fig. 1)
and the CH235 autologous nAb lineage (Fig. 4) is striking and suggests a fundamental
difference in their biology. Whereas the CH235 autologous nAb lineage led to total escape
from all lineage members after 30 weeks of infection (Fig. 4), the CH103 bnAb lineage
differed in that it was comprised of two components, the early autologous-only nAbs (UCA
through IA4), and the more mature antibodies (IA3 through CH103, CH104, CH105 and
CH106 bnAbs) with neutralization breadth (Fig.1). The early CH103 autologous-only nAbs
also select total escape by week 53, but the later CH103 antibodies with neutralization
breadth did not. Rather, the more mature CH103 bnAbs retained the ability to neutralize
select autologous variants through week 100 (Fig. 1). These data suggested that a component
of bnAb development is the retention of ability to neutralize autologous variants as bnAbs
acquire the ability to neutralize heterologous HIV-1 variants. Thus, the cooperation between
the autologous nAb CH235 lineage and the CH103 bnAb lineage demonstrated the first step
in bnAb lineage development in which a bnAb lineage retained the ability to neutralize
autologous virus variants as they matured to neutralize heterologous viruses. It is critical to
determine if the types of cooperating lineages as seen in CH235-CH103 interactions are the
key initiators of bnAb breadth, or rather if other additional Env-reactive B cell lineages are
required. Against this latter notion was the observation that multiple loop D Env mutants can
likely drive all stages of the CH103 lineage (Fig. 3).
It is important to note that the CH103 bnAb is a loop binding CD4bs bnAb in contrast to the
VRC01-type of CD4bs bnAb that binds the CD4 binding site in a manner similar to CD4
(Zhou et al., 2013). Whereas VRC01-like mAbs derive from restricted VHDJH/VLJL pairing
of VH1-2*02 or VH1-46 paired with a VLJL with a 5-amino acid LCDR3, new loop binding
CD4bs bnAbs have been isolated and can utilize multiple VHDJH/VLJL pairs (Bonsignori et
al., 2014; Liao et al., 2013a; Mascola JR et al. unpblished data). It will be important to
determine, with immunization of CH505 Envs, if either CH103-like VH4-59, Vλ3-1 CD4bs
lineage Abs are induced, or if other VH usage can be induced with CD4bs bnAb signatures.
These findings have considerable importance for HIV-1 vaccine design for induction of
CD4bs bnAbs. First, mapping of only bnAb lineages over time in those individuals who
make them may not be sufficient for obtaining the information needed for the design of
protective immunogens for bnAb development. Rather, mapping autologous neutralizing
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antibody lineages that are not within the bnAb lineage may also be required for optimal
choice of immunogen candidates. Second, these data suggest that induction of one or more
autologous bnAb lineages to select Env variants with enhanced affinity for bnAb lineage
antibody members may be required to induce CH103-like CD4 bs HIV-1 neutralizing
antibodies. For example, for CH103-like lineage induction, priming with the transmitted/
founder Env and additional Envs variants such as M6V281A with enhanced binding to
CH235 lineage antibodies, followed by boosting with Env mutants with enhanced binding to
CH103 lineage members is likely to be important for experimental vaccine design.
Experimental Procedures
Generation of pseudoviruses
Env pseudoviruses were produced as described (Kirchherr et al., 2007).
Neutralization assay
Neutralization activity was measured as a reduction in luciferase activity after a single round
infection of TZM-bl cells as previously described (Li et al., 2005; Montefiori, 2004).
IFN-γ ELISpot assay
The IFN-γ ELISpot assay was performed according to the previously described (Cox et al.,
2006). The responses were considered positive if >50 SFC per 106 PBMCs were detected.
Site-directed mutagenesis
Mutants of CH0505.T/F envelope gene were constructed using the Quick Change II Site-
Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA). All final env mutants
were confirmed by sequencing.
Viral fitness assay
The fitness of the Env loop D mutants was determined by comparing to their cognate CH505
T/F virus in a competitive fitness assay as previous described (Cai et al., 2007; Song et al.,
2012).
Envelope glycoprotein expression
The codon-optimized CH505 transmitted/founder and loop D mutant env genes were
generated by de novo synthesis (GeneScript, Piscataway, NJ) or site-directed mutagenesis in
mammalian expression plasmid pcDNA3.1/hygromycin (Invitrogen, Grand Island, NY) as
described (Liao et al., 2013b), and stored at −80°C until use.
B Cell Culture
IgG+ memory cells were isolated from PBMCs using a previously described protocol
(Bonsignori et al., 2011). Cell culture supernatants were screened for binding to autologous
CH505 T/F gp140 and neutralization of the autologous CH505 w4.3 Env pseudovirus.
Culture supernatants that neutralized CH505 w4.3 were then screened for differential
neutralization of the CH505 T/F and M10 mutant viruses.
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Isolation of immunoglobulin V(D)J and VL gene segments and expression of recombinant
antibodies
RNA from positive cultures was extracted by using standard procedures (RNeasy minikit;
Qiagen, Valencia, CA), and the genes encoding Ig VHDJH and VLJL rearrangements were
amplified by RT and nested PCR without cloning by use of a previously reported method
(Liao et al., 2009). Sequence base calling was performed by using Phred. V, D, and J region
genes and mutations were analyzed by using the SoDA information system (Volpe et al.,
2006). The genetic information of the Ig VHDJH and VLJL were annotated using the method
as described (Liao et al., 2013a). For further characterization, the isolated VHDJH/VLJL
genes of the observed antibodies from CH505 and inferred VHDJH/VLJL for UCAs and
intermediate antibodies were synthesized (GenScript, Piscataway, NJ) and cloned into
pcDNA3.1 plasmid (Invitrogen, Grand Island, NY) for production of purified recombinant
IgG1 antibodies in 293F cells by transient transfection as described previously (Liao et al.,
2011).
Inference of UCA and IAs of CH235 lineage
The six members of the CH235 antibody lineage were used to infer the UCA and IAs of
both heavy and light chains simultaneously using methods described in (Kepler, 2013).
Direct Binding ELISA
Direct binding assays were performed in 384-well plates as previously described
(Bonsignori et al., 2011).
Surface plasmon resonance (SPR) affinity and kinetics measurements
Binding KD and rate constant (association rate kA, dissociation rate kD) measurements of
mAbs to the autologous Env C. CH05 gp140 were carried out on BIAcore 3000 or BIAcore
T200 instruments as described earlier (Alam et al., 2007; Alam et al., 2009; Liao et al.,
2013a).
Structural alignment and loop modeling
To visualize effects of evolutionary mutations in CH505 variants, such as sequence
insertions and addition of potential glycosylation sites, in the trimeric viral spike context, the
antibody CH103-gp120 complex structure (PGB ID: 4JAN) was aligned to the structure of
BG505 SOSIP.664 HIV-1 Env trimer in complex with VRC-PG04 (PGB ID: 3J5M) by
superposing the outer domains of gp120 in each structure using program package CCP4
(Winn et al., 2011). Based on the superposed CH103 gp120 structure, possible
conformations of loop insertions in the HIV-1 V1-, V2- and V5-loop were modeled with
program Loopy (Xiang et al., 2002). Relative positions and potential clashes between the
HIV-1 V1-, V2- and V5-loop and the gp120-bound CH103 were depicted with program
PyMOL (http://www.pymol.org).
Calculation of changes in binding energy upon mutation
To analysis how the evolutionary mutations in loop D of CH505 gp120 and affinity
maturation mutations in antibody CH103 affected their affinity and neutralization
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sensitivity, we calculated the predicted changes in binding energy (ΔΔG, kcal/mol) caused
by each mutation on either loop D of gp120 or CHR L2 of antibody CH103. The
computational procedure were performed on a web-based program BeAtMuSiC (Dehouck et
al., 2013; Moretti et al., 2013) which evaluates the change in binding affinity between two
proteins caused by single-site mutations in their sequence based on known structure of the
protein-protein complex. Since we only have the complex structure of mature antibody
CH103 in complex with gp120 (PGB ID: 4JAN), the calculations were carried by reverting
respective amino acid at each position (275, 279 and 281 in the HIV-1 loop D and 50–52 in
CH103 CDR L2) to its counterpart in the T/F virus or germline antibody.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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- The steps in induction of HIV-1 broad neutralizing antibodies have been
mapped.
- The steps involve cooperation between two distinct B cell antibody lineages.
- One lineage induced escape mutants with enhanced binding to bnAb
precursors.
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Figure 1. Neutralization activity of CH103 clonal lineage antibodies against autologous CH505
viruses
Heat map analysis of neutralization data generated from 124 pseudoviruses (row) and 13
CH103 lineage mAbs (column). The neutralization potency (IC50) is shown in different
shades of colors as indicated in the histogram; from white (>50µg/ml) to dark red (0.079 µg/
ml). The Env pseudoviruses were generated for the CH505 T/F virus and variants from
weeks 4 – 100 and were all assayed against the unmutated common ancestor (UCA),
intermediate antibodies (IA8-1) and mature bnAbs (CH103-106) in the TZM-bl cell-based
neutralization assay. The resistant viruses (blue brackets) were defined as those with the
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average IC50 values 1.8 fold high than that of the T/F pseudoviruses for later IAs (IA3-IA1)
and all mature Abs. The week 30 viruses that fully escaped from the early IAs (IA8-IA4) are
also indicated by blue bracket. See also Table S1; Figures S1 and S4.
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Figure 2. Association of insertions in V1 and V5 with neutralization escape from CH103 lineage
mAbs
The V1 (A) and V5 (B) amino acid sequences at week 30 were compared to the CH505 T/F
sequence. The neutralization sensitive viruses to early IAs (IA8-4) and late IAs (IA3-1)/
mature CH103 lineage mAbs (CH103-106) are indicated in red and blue, respectively. The
potential N-linked glycosylation (PNLG) sites are indicated in yellow. The identical amino
acids are shown as dashes and deletions are shown as dots. See also Figures S1 and S2.
Gao et al. Page 18






















Figure 3. Mutations in loop D rendered the Env mutants more sensitive to CH103 lineage bnAb
neutralization with enhanced Env binding
(A) Alignment of nine amino acids in loop D of Env. The amino acid sequences from week
4 to week 160 were compared to the CH505 T/F sequence. The number and frequency of
each variant in loop D are shown at the right of the alignment. The two asparagines (N)
whose side chains interact with the CH103 light chain are indicated in yellow. The loop D
mutations that occurred early or predominated are indicated in red, and Env mutants
containing those mutations are indicated by red arrows. (B) Neutralization susceptibility of
the loop D mutants by the CH103 lineage mAbs. Heatmap analysis was performed for the
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neutralization data of all CH103 lineage mAbs (column) against the CH505 T/F virus and
the loop D variants (row). The neutralization potency (IC50) is shown in different colors as
indicated; from white (>50 µg/ml) to dark red (0.12 µg/ml). (C) Neutralization activity of the
nAb CH235 were compared to that of the bnAb CH103 against the CH505 T/F virus and
loop D mutants. (D) The fold difference in binding to loop D mutant Envs versus the CH505
T/F Env by both CH103 and CH235 lineage Abs. Seven loop D mutant Envs (M6V281A,
M10V281G, M11N279D/V281G, M7E275K/N279D/V281S, M8N280S/V281A, M9E275K/N279D/V281G
and M21N280T/V281A) and the CH505 T/F Env were serially diluted and the log area under
the curve (AUC) values for all members of the CH103 and CH235 lineage mAbs were
determined by ELISA. The fold difference in log AUC between each loop D mutant Env
versus the CH505 T/F Env is shown. See also Figures S3, S4 and S6; Tables S2, S3 and S6.
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Figure 4. Neutralization activity of the CH235 clonal lineage antibodies against autologous
CH505 viruses
Heatmap analysis of neutralization data generated from 41 pseudoviruses (row) and 10
CH235 lineage mAbs (column). The neutralization potency (IC50) is shown in different
shades of colors as indicated in the histogram; from white (>50 µg/ml) to dark red (0.1
µg/ml) (see also Table S4). The CH505 T/F and select variant Env pseudoviruses from each
time time point (weeks 4-100) were assayed against the unmutated common ancestor
(UCA), intermediate antibodies (IA4-1) and mature autologous neutralizing antibodies
(CH235, CH236, CH239, CH240 and CH241) in the TZM-bl cell-based neutralization
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assay. The partially and fully resistant viruses are indicated by the blue bracket. See also
Figure S5 and Table S4.
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Figure 5. Neutralization activity of CH235 clonal lineage antibodies against CH505 Env loop D
mutants
Heat map analysis of neutralization data generated from 10 loop D mutants (row) and 10
CH235 lineage mAbs (column). The neutralization potency (IC50) is shown in different
shades of colors as indicated in the histogram; from white (>50 µg/ml) to dark red (0.1 µg/
ml). The CH505 T/F and loop D mutant Env pseudoviruses were assayed against the
unmutated common ancestor (UCA), intermediate antibodies (IA4-1) and mature autologous
neutralizing antibodies (CH235, CH236, CH239, CH240 and CH241) in the TZM-bl cell-
based neutralization assay. The partially and fully resistant viruses are indicated by the blue
bracket. See also Table S5.
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Figure 6. Evolutionary mutations in the Loop D and antibody facilitate interactions between
gp120 and CH103 lineage antibodies
(A) Model of CH505 T/F gp120 in complex with UCA of CH103. (B) Model of loop D
mutant M7E275K/N279D/V281S gp120 in complex with mature CH103. The gp120 is shown in
semi-transparent electrostatic potential surface with red for negative charge and blue for
positive charge. The heavy and light chains of the CH103 bnAb are shown in green and
orange, respectively. All critical mutations in loop D and CDR L2 are highlighted in sticks
and colored in cyan for residues (279 and 281) in loop D, orange for conserved CDR L2
Lys53, and blue for mutated CDR L2 residues 50–52. (C) Calculated binding energy change
(ΔΔG) when specified residues were reverted back to the T/F or germline sequences for
gp120 and CH103 light chain, respectively. All revertants (except the non-interfacial loop D
Lys275) resulted in unfavorable ΔΔG changes (indicated in red in panels a and b)
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suggesting that the evolution of both gp120 loop D and CDR L2 of CH103 facilitated the
interaction between HIV-1 gp120 and mature CH103 antibodies.
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Figure 7. Schema of Cooperation of B Cell Lineages in Induction of HIV-1 Broadly Neutralizing
Antibodies
The T/F Env (red Env trimer) likely initiated both the CH235 and CH103 lineages by
binding to their UCA. The CH235 lineage (dark blue), selected viral escape mutations in
loop D of the CH505 T/F virus (blue Env timer) at week 53. The CH103 lineage gradually
accumulated mutations that led to acquisition of bnAb activity as CH103 lineage affinity
maturation progressed. The loop D mutant Envs more avidly bound CH103 IAs and mature
antibodies than the T/F Env and thus cooperated with the T/F Env to drive CH103 bnAb B
cell lineage development.
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